Celltrion: Preliminary consolidated earnings report
AI reading
★★★ Bullish · Earnings
Q3 revenue and operating profit rise from prior quarter and year earlier
Key figures: Revenue ₩1.5tn, up 7.63% on quarter; operating profit ₩510bn, up 12.88%
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
Other filings by Celltrion
- 09.23 ★★★ Celltrion: FDA clears Phase 3 trial for Zymfentra in rheumatoid arthritis
- 09.23 ★★ Files report on major shareholding
- 09.21 ★★★ Celltrion: EMA clears Phase 3 trial for Darzalex biosimilar
- 09.16 ★★ Company announces share retirement to boost shareholder value
- 09.07 ★★★ Celltrion: FDA approves amended Phase 3 trial plan for Keytruda biosimilar
- 09.07 ★★★ Celltrion: MFDS approves amended Phase 3 trial plan for Darzalex biosimilar in Korea
For information only. Not investment advice.